Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Actelion Pharmaceuticals

Status

Conditions: Thromboangiitis Obliterans; Non-healing Wound

Treatments: Drug: Selexipag

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04914247

CR108669

67896049PAH4002 (Other Identifier)

Details and patient eligibility

About

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria